{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:29:17Z","timestamp":1763551757582},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2014,5,28]],"date-time":"2014-05-28T00:00:00Z","timestamp":1401235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Italian Association for Leukemias, Lymphomas, and Myeloma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The definition of the role of positron emission tomography (PET) in peripheral T-cell lymphomas (PTCLs) is still under investigation. The purpose of the present observational retrospective study was to assess the early prognostic value of PET after the first three cycles of therapy (PET+3), evaluating visual data in de novo PTCL patients treated in first line with standard chemotherapy and followed by both PET and computed tomography scan. Of 27 PET+3-negative patients, 19 also had a negative PET at the end of treatment (PET+6), whereas 8 of 27 had a positive final one; 6 of 7 PET+3-positive patients had a positive PET+6, whereas only 1 patient had a negative PET+6. Estimated overall survival plotted according to PET+3 results showed 78.6% for negative patients and 21.4% for positive patients at 88.7 months with a significant difference. Patients with negative PET+3 had superior progression-free survival of 72.6% compared with 16.7% of PET+3-positive patients. At the time of this analysis, 17 of 19 (89.5%) patients with negative PET+3 are in continuous complete response (CCR) and only 1 of 7 (14.2%) patients with positive PET+3 is still in CCR. In conclusion, our results indicate that positive PET+3 is predictive of a worse outcome in PTCL, and this significant statistical difference between the two curves could be clinically informative. Larger and prospective studies and harmonization of PET reading criteria are needed.<\/jats:p>","DOI":"10.1634\/theoncologist.2013-0463","type":"journal-article","created":{"date-parts":[[2014,5,29]],"date-time":"2014-05-29T03:07:59Z","timestamp":1401332879000},"page":"746-750","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic Value of Interim Positron Emission Tomography in Patients With Peripheral T-Cell Lymphoma"],"prefix":"10.1093","volume":"19","author":[{"given":"Cinzia","family":"Pellegrini","sequence":"first","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Derenzini","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Letizia","family":"Gandolfi","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Maglie","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[{"name":"Institute of Hematology \u201cL. and A. Ser\u00e0gnoli,\u201d Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,5,28]]},"reference":[{"key":"2021122309082264200_B1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5","article-title":"2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial","volume":"91","author":"Buchmann","year":"2001","journal-title":"Cancer"},{"key":"2021122309082264200_B2","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1148\/radiology.190.1.8259386","article-title":"Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT","volume":"190","author":"Newman","year":"1994","journal-title":"Radiology"},{"key":"2021122309082264200_B3","first-page":"234","article-title":"Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma","volume":"36","author":"Thill","year":"1997","journal-title":"Nucl Med (Stuttg)"},{"key":"2021122309082264200_B4","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","volume":"25","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309082264200_B5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/annonc\/mdl122","article-title":"Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients","volume":"17","author":"Zinzani","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122309082264200_B6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00006231-199901000-00004","article-title":"Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma","volume":"20","author":"Jerusalem","year":"1999","journal-title":"Nucl Med Commun"},{"key":"2021122309082264200_B7","first-page":"1643","article-title":"PET\/CT in lymphoma: Prospective study of enhanced full-dose PET\/CT versus unenhanced low-dose PET\/CT","volume":"47","author":"Rodr\u00edguez-Vigil","year":"2006","journal-title":"J Nucl Med"},{"key":"2021122309082264200_B8","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1182\/blood-2002-09-2778","article-title":"Utility of FDG-PET scanning in lymphoma by WHO classification","volume":"101","author":"Elstrom","year":"2003","journal-title":"Blood"},{"key":"2021122309082264200_B9","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdm265","article-title":"FDG-PET in T-cell and NK-cell neoplasms","volume":"18","author":"Kako","year":"2007","journal-title":"Ann Oncol"},{"key":"2021122309082264200_B10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.2967\/jnumed.108.053355","article-title":"Prognostic value of tumor 18F-FDG uptake in patients with untreated extranodal natural killer\/T-cell lymphomas of the head and neck","volume":"49","author":"Suh","year":"2008","journal-title":"J Nucl Med"},{"key":"2021122309082264200_B11","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3816\/CLM.2008.n.010","article-title":"The value of [18F]fluorodeoxyglucose positron emission tomography\/computed tomography in extranodal natural killer\/T-cell lymphoma","volume":"8","author":"Karantanis","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"2021122309082264200_B12","first-page":"1622","article-title":"18F-FDG PET versus CT for the detection of enteropathy-associated T-cell lymphoma in refractory celiac disease","volume":"47","author":"Hadithi","year":"2006","journal-title":"J Nucl Med"},{"key":"2021122309082264200_B13","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"2021122309082264200_B14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00277-008-0494-8","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies","volume":"87","author":"Khong","year":"2008","journal-title":"Ann Hematol"},{"key":"2021122309082264200_B15","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/RLU.0b013e3181e4dcbf","article-title":"Metabolic activity measured by F-18 FDG PET in natural killer-cell lymphoma compared to aggressive B- and T-cell lymphomas","volume":"35","author":"Chan","year":"2010","journal-title":"Clin Nucl Med"},{"key":"2021122309082264200_B16","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3109\/10428194.2013.767901","article-title":"18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma","volume":"54","author":"Casulo","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2021122309082264200_B17","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"2021122309082264200_B18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.2006.08.2305","article-title":"Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma","volume":"25","author":"Juweid","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309082264200_B19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309082264200_B20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2214\/AJR.08.1398","article-title":"CT and PET\/CT findings of T-cell lymphoma","volume":"193","author":"Otero","year":"2009","journal-title":"AJR Am J Roentgenol"},{"key":"2021122309082264200_B21","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2967\/jnumed.112.110262","article-title":"Prognostic value of interim and posttherapy 18F-FDG PET\/CT in patients with mature T-cell and natural killer cell lymphomas","volume":"54","author":"Li","year":"2013","journal-title":"J Nucl Med"},{"key":"2021122309082264200_B22","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/annonc\/mdq415","article-title":"18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T\/NK lymphomas: A study from the GOELAMS group","volume":"22","author":"Cahu","year":"2011","journal-title":"Ann Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2013-0463","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0463","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/7\/746\/41862563\/oncolo_19_7_746.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/7\/746\/41862563\/oncolo_19_7_746.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:06:45Z","timestamp":1640311605000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/7\/746\/6399351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,28]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,5,28]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0463","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7,1]]},"published":{"date-parts":[[2014,5,28]]}}}